Navigation Links
Lilly Reports on Outcome of Phase III Study of Arzoxifene
Date:8/18/2009

INDIANAPOLIS, Aug. 18 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women. However, the study failed to demonstrate a statistically significant difference in key secondary efficacy endpoints, such as non-vertebral fractures, clinical vertebral fractures, cardiovascular events and cognitive function, compared to placebo. In addition, certain adverse events, including venous thromboembolic events, hot flushes and gynecological-related events, were reported more frequently in the arzoxifene group compared with placebo. After reviewing the overall clinical profile of arzoxifene in light of currently available treatments, including Lilly's own osteoporosis products, the company has decided not to submit the compound for regulatory review. The final GJAD "GENERATIONS" study results will be published in 2010.

"At Lilly, our goal is to provide innovative therapies that result in better patient outcomes," said M. Johnston Erwin, global brand development leader for the musculoskeletal platform at Lilly. "While arzoxifene met its primary efficacy objectives in this study, we are disappointed that the GENERATIONS data did not convincingly demonstrate that arzoxifene would represent a meaningful advancement in the treatment of osteoporosis."

"The results of arzoxifene's GENERATIONS study serve as a reminder of the high risks associated with pharmaceutical innovation," commented John Lechleiter, Ph.D., Lilly chairman and chief executive officer. "Despite this setback, our business remains strong, supported by the growth of key marketed products. In
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. U.S. District Court Rules Against Lilly Regarding Gemzar Patent
2. Eli Lilly-Children International Launches Teen Campaign to Reduce TB Cases in India
3. Lilly Broadens Income Eligibility for Patient Assistance Programs
4. Lilly Announces Continued Commitment to Transparency with Faculty Registry
5. Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting
6. Lilly Receives Award From National Medical Association
7. FDA Approves Expanded Use of Lillys FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
8. Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
9. Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
10. Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
11. Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... A Forever Recovery , an ... off to a great start and gives them a ... launched a new Eating Disorders section of its website ... , Different types of eating disorders ... Disorders (DSM-IV), including anorexia nervosa, bulimia nervosa, and EDNOS ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Men who have a ... cancer, a new study suggests. But the risk ... not involved with the study said more research is ... accurate. For the study, Harvard researchers analyzed data ... for 24 years, starting in 1986. During that time, ...
(Date:7/10/2014)... aggression, who research issues ranging from child abuse to ... of the International Society for Research on Aggression (ISRA) ... State University is hosting the prestigious world meeting, which ... "We are excited to be bringing together leading scholars ... produce fresh ideas about the causes, consequences and solutions ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... Mothers who are depressed respond differently to their crying ... according to brain scans at the University of Oregon, ... in non-depressed moms. An infant crying is normal, ... says Jennifer C. Ablow, professor of psychology. For years, ...
... This release is available in Spanish . ... and cooperators have confirmed what many pollen-sensitive people already suspected: ... longer and ends later. Ragweed pollen in some ... almost a month longer than it did in 1995, and ...
... , TUESDAY, Feb. 22 (HealthDay News) -- Despite suggestions ... skin condition known as atopic eczema, a new British ... to relieve sufferers. "Although the outcome is disappointing ... eczema, the outcome of the trial is very clear," ...
... HealthDay Reporter , TUESDAY, Feb. 22 (HealthDay News) -- ... increased risk of ischemic stroke, which typically occurs when blood ... fatty deposits within blood vessels, a new Danish study contends. ... pronounced for triglyceride fats than it is for cholesterol, even ...
... researcher believes there could be a new drug compound ... also help with controlling cholesterol. Salman Hyder, the ... biomedical sciences in the College of Veterinary Medicine and ... discovered that a small molecule, Ro 48-8071, initially developed ...
... leap forward in understanding Huntington,s disease may give patients ... cells and post-mortem brain tissue of Huntington,s disease patients ... that causes brain nerve cells to die. Toning down ... the chain reaction and kept those cells alive, according ...
Cached Medicine News:Health News:Crying baby draws blunted response in depressed mom's brain 2Health News:Crying baby draws blunted response in depressed mom's brain 3Health News:USDA study confirms links between longer ragweed season and climate change 2Health News:Softening Water Does Not Seem to Ease Eczema 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 3Health News:Compound used to block cholesterol could also kill breast cancer, MU researcher finds 2Health News:Huntington's disease breakthrough equals hope for patients 2
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... against cancers and infectious diseases, announced today that the ... technology at the 14th Annual Meeting of the American ... May 18-21 in Seattle, Washington at the Washington State ...
... Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" ... first quarter ended March 31, 2011. F ... Highlights Total revenue increased to $9.4 million ... Net cash provided by operating activities was approximately $2.6 ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011 2Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011 3Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011 4China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011 2China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011 3China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011 4China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011 5China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011 6China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011 7China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011 8
... interoperative placement to stent the ... and continent urinary diversions. Supplied ... for one-time use. CAUTION: Periodic ... not remain indwelling more than ...
... a device that provides effective cutting and simultaneous ... to provide the urologist with the same touch ... the approximate speed and the same ease of ... but with a 45% greater zone of ...
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: